Lyell Immunopharma (LYLE) is positioned for significant upside due to its ronde-cel therapy, which demonstrates best-in-class durability and safety in treating relapsed/refractory large B-cell lymphoma (LBCL). Despite trading near cash value, the market undervalues its pipeline, which includes advanced pivotal trials and promising early efficacy signals. Ronde-cel’s dual targeting of CD19/CD20 and CD62L+ enrichment contribute to durable responses, low severe toxicity, and potential outpatient use. Key upcoming catalysts include data from the PiNACLE trial expected in the second half of 2026 and a cash runway extending to the third quarter of 2027, which could drive a re-rating of the company’s valuation if executed successfully.
Virtuals Protocol has introduced customizable tokenized indexes on the Robinhood Chain, allowing users to combine multiple assets into a single token. This innovation enables users to create and manage their own asset baskets and earn fees when other...
US spot Bitcoin ETFs saw net inflows of $107.8 million on Wednesday, while Ethereum ETFs attracted $53.8 million, signaling renewed institutional interest in crypto funds. Since their launch in January 2024, Bitcoin ETFs have accumulated over $51 bil...
Kaia has signed a strategic partnership with Xilo Labs to integrate Mochi, an onchain asset management platform, into Kaia's ecosystem. This collaboration allows users to invest stablecoins into diversified portfolios backed by tokenized real-world a...
Bitcoin's price surged to nearly $65,000 following softer-than-expected U.S. inflation data for June, easing fears of Federal Reserve rate hikes. However, on-chain data reveals two main groups of investors—long-term holders who bought near last year'...
Bitcoin miners are experiencing declining revenue as the network's hash rate and mining difficulty fall, reflecting a shift of miners into AI infrastructure. Despite this stress, miners are accumulating Bitcoin, with reserves increasing by 1%, signal...
